1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. China National Medicines Corporation Ltd.
  6. Summary
    600511   CNE000001D56

CHINA NATIONAL MEDICINES CORPORATION LTD.

(600511)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-08-15
25.60 CNY   +0.04%
07/08Sinopharm Mulls $1 Billion Purchase of DNA Products Supplier BBI Life Sciences
MT
06/20CHINA NATIONAL MEDICINES CORPORATION LTD.(XSSC : 600511) dropped from S&P Global BMI Index
CI
06/13CHINA NATIONAL MEDICINES CORPORATION LTD.(XSSC : 600511) dropped from FTSE All-World Index
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
08/10/2022 08/11/2022 08/12/2022 08/15/2022 08/16/2022 Date
25.46 25.75 25.75 25.59 25.6 Last
2899423 3928020 2865457 2713713 2368611 Volume
-0.93% +1.14% 0.00% -0.62% +0.04% Change
Estimated financial data (e)
Sales 2022 50 651 M 7 462 M 7 462 M
Net income 2022 1 929 M 284 M 284 M
Net Debt 2022 - - -
P/E ratio 2022 9,96x
Yield 2022 3,48%
Sales 2023 56 360 M 8 303 M 8 303 M
Net income 2023 2 161 M 318 M 318 M
Net Debt 2023 - - -
P/E ratio 2023 8,95x
Yield 2023 3,91%
Capitalization 19 315 M 2 846 M 2 846 M
Capi. / Sales 2022 0,38x
Capi. / Sales 2023 0,34x
Nbr of Employees -
Free-Float 42,0%
More Financials
Company
China National Medicines Corporation Ltd. is a China-based company principally engaged in the distribution of pharmaceutical products. The Company's primary products include proprietary Chinese medicines, chemical medicine preparations, chemical raw materials, antibiotics, biochemical drugs, biological products, narcotic drugs, psychotropic drugs, vaccines and health foods, among others. The Company is also involved... 
Sector
Pharmaceuticals
Calendar
08/24Earnings Release
More about the company
Ratings of China National Medicines Corporation Ltd.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about CHINA NATIONAL MEDICINES CORPORATION LTD.
07/08Sinopharm Mulls $1 Billion Purchase of DNA Products Supplier BBI Life Sciences
MT
06/20CHINA NATIONAL MEDICINES CORPORATION : 600511) dropped from S&P Global BMI Index
CI
06/13CHINA NATIONAL MEDICINES CORPORATION : 600511) dropped from FTSE All-World Index
CI
06/10CHINA NATIONAL MEDICINES CORPORATION : 600511) dropped from SSE 180 Index
CI
06/10CHINA NATIONAL MEDICINES CORPORATION : 600511) dropped from Shanghai Stock Exchange 180 Va..
CI
04/27Chinese Shares Rebound Strongly; Sinopharm Jumps 6% on Clinical Trial Approval
MT
04/26Sinopharm Unit Wins Nod to Test Omicron Vaccine in China
MT
04/19China National Medicines Corporation Ltd. Reports Earnings Results for the First Quarte..
CI
03/17China National Medicines Posts Higher Earnings in 2021; Shares Rise 4%
MT
03/16China National Medicines Corporation Ltd. Reports Earnings Results for the Full Year En..
CI
2021China National Medicines Corporation Ltd. Reports Earnings Results for the Nine Months ..
CI
2021China National Medicines Corporation Ltd. Reports Earnings Results for the Half Year En..
CI
2021CHINA NATIONAL MEDICINES CORPORATION : 600511) added to SSE 180 Index
CI
2021CHINA NATIONAL MEDICINES CORPORATION : 600511) added to Shanghai Stock Exchange 180 Value ..
CI
2021China National Medicines Corporation Ltd. Reports Earnings Results for the First Quarte..
CI
More news
News in other languages on CHINA NATIONAL MEDICINES CORPORATION LTD.
07/08Sinopharm envisage d'acheter pour 1 milliard de dollars le fournisseur de produits ADN ..
04/27Les actions chinoises rebondissent fortement ; Sinopharm bondit de 6 % après l'approbat..
04/26Une unité de Sinopharm obtient le feu vert pour tester le vaccin Omicron en Chine
04/19China National Medicines Corporation Ltd. annonce ses résultats pour le premier trimest..
03/17China National Medicines affiche des bénéfices plus élevés en 2021 ; les actions augmen..
More news
Chart CHINA NATIONAL MEDICINES CORPORATION LTD.
Duration : Period :
China National Medicines Corporation Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHINA NATIONAL MEDICINES CORPORATION LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 25,60 CNY
Average target price 39,20 CNY
Spread / Average Target 53,1%
EPS Revisions
Managers and Directors
Xiu Chang Jiang Director
Jing Yun Liu Member-Supervisory Board
Peng Ren Independent Director
Feng Zhen Liu Independent Director
Lian Qi Zhang Independent Director